

December 16, 2016



**DCAT**  
**TOP** ↑  
**Industry**  
**NEWS**

***BUSY WEEK?** Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*



**Patheon**  
A HEALTHIER WORLD. DELIVERED.

**Executive insights. Delivered.**

[Learn more](#)

**1. [Lonza To Acquire Capsugel for \\$5.5 Billion](#)**

Lonza has agreed to acquire Capsugel, a provider of dosage forms and technologies, from the private-equity firm KKR for \$5.5 billion in cash. Lonza is making good on its previously announced intent to build drug-product development and manufacturing capabilities to complement its core capabilities in small-molecule and biologic-based active pharmaceutical ingredient development and manufacturing.

[Read More](#)

**2. [BMS Invests in Biologics Support, Makes US Site Changes](#)**

Bristol-Myers Squibb has announced investments in its US facilities to strengthen capabilities of its R&D hubs in Central New Jersey, the San Francisco Bay Area, and Cambridge, Massachusetts while further integrating biologics development with clinical manufacturing at key sites. It will also proceed with site closures in Wallingford, Connecticut; Hopewell, New Jersey; and Seattle, Washington. [Read More](#)

**3. [Monsanto Shareholders Approve \\$66 Billion Merger with Bayer](#)**

Bayer has cleared one hurdle in its proposed \$66 billion acquisition of Monsanto, an agrochemical and seed company, with the shareholders of Monsanto approving the deal. Bayer came to terms with Monsanto for a proposed acquisition in September 2016. The move is the first-large scale acquisition by Bayer since becoming a pure-play life sciences company with a focus on pharmaceuticals, consumer healthcare, and crop science following spinning out its material sciences business in 2015.

[Read More](#)

**4. [J&J Ends Transaction Discussions with Actelion](#)**

Johnson & Johnson (J&J) has ended discussions with Actelion Pharmaceuticals, a Swiss biopharmaceutical company, regarding a potential transaction. In late November 2016, J&J had confirmed it was in talks with the Swiss biopharmaceutical firm, which is focused on drugs for pulmonary arterial hypertension, a rare-disease area. [Read More](#)

**5. [Baxter to Acquire Claris Injectables in \\$625-Million Deal](#)**

Baxter International has agreed to acquire Claris Injectables, a generic injectables pharmaceutical company based in Ahmedabad, India, for \$625 million. [Read More](#)

**6. [Sanofi Plans 20% Reduction in Diabetes, Cardiovascular Workforce](#)**

Sanofi has announced an approximate 20% reduction in staff at its US diabetes and cardiovascular business unit as part of a new realignment. The staff reductions are in the sales force and some business support functions. The move comes as the company faces increased generic competition for its top-selling drug Lantus (insulin glargine recombinant). [Read More](#)

#### 7. [Perrigo to Restructure Branded Consumer Healthcare Biz](#)

Perrigo has announced its intention to restructure its Branded Consumer Healthcare's Omega Pharma Belgium business to improve the financial profile and enhance focus of the business on branded consumer over-the-counter products. Perrigo had acquired Omega Pharma in 2015 for EUR 3.8 billion (\$3.95 billion) [Read More](#)

#### 8. [Mylan Granted US Patent Review of Allergan Eye-Care Drug](#)

Mylan has been granted Inter Partes Reviews of patents for Allergan's blockbuster eye-care drug, Restasis (cyclosporine ophthalmic emulsion), by the US Patent & Trademark Office's Patent Trial and Appeal Board. Restasis is one of Allergan's top-selling drugs with global sales of \$1.08 billion in the first nine months of 2016. [Read More](#)

#### 9. [GSK Opens New Vaccines R&D Facility](#)

GlaxoSmithKline has opened a new global vaccines R&D center in Rockville, Maryland and will be investing more than \$50 million in the next two years to continue to develop the site. [Read More](#)

#### 10. [Perrigo Sells India API Manufacturing Plant to Strides Shasun](#)

Perrigo has agreed to sell its entire shareholding in Perrigo API India to Strides Shasun, a Bangalore, India-based pharmaceutical company, for Indian rupee 1000 million (\$14.8 million). The transaction includes an active pharmaceutical ingredient manufacturing plant in Ambarnath, Maharashtra with a potential capacity of 600 tons per year. The companies also formed a long-term supply agreement. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.  
This will be the last issue of Top Industry News for 2016.  
Our next issue will be Friday January 6, 2017.  
Happy Holidays and Happy New Year!*

### **About Top Industry News**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599

[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)